TransGenic Group

TransGenic Group EPS

The Earnings per Share (EPS) of TransGenic Group (2342.T) as of Nov 11, 2026 is -4.64 JPY. In the previous year, Earnings per Share (EPS) was -65.43 JPY — a change of -92.91% (higher).

EPS

-4.64JPY

YoY

-92.91%

Last updated:

Earnings per Share (EPS) of TransGenic Group is 2026 -4.64 JPY. Earnings per Share (EPS) of TransGenic Group was 2025 -65.43 JPY. It decreases by -92.91% higher compared to the previous year.

The TransGenic Group EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
11.64 JPY
Jan 1, 2020
-25.38 JPY
Jan 1, 2021
32.48 JPY
Jan 1, 2022
111.30 JPY
Jan 1, 2023
-24.31 JPY
Jan 1, 2024
0.25 JPY
Jan 1, 2025
-65.43 JPY
Jan 1, 2026
-4.64 JPY
The TransGenic Group EPS history
YEAREPSYoY
-4.64JPY-92.91%
-65.43JPY-26,774.22%
0.25JPY-101.01%
-24.31JPY-121.84%
111.30JPY+242.66%
32.48JPY-228.01%
-25.38JPY-317.94%
11.64JPY+854.28%
1.22JPY-77.52%
5.43JPY+434.14%
1.02JPY-5.05%
1.07JPY-115.68%
-6.82JPY-520.15%
1.62JPY-117.31%
-9.38JPY-27.49%
-12.94JPY-62.79%
-34.77JPY-8.80%
-38.12JPY-28.22%
-53.11JPY+33.15%
-39.89JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Earnings per Share (EPS) of TransGenic Group is -4.64 JPY in 2026.

Earnings per Share (EPS) of TransGenic Group changed from -65.43 JPY to -4.64 JPY, representing a -92.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TransGenic Group

All Key Metrics — TransGenic Group